Home > Insider Trading > Filing (0001140361-17-018662)

Filing Details

Accession Number:: 0001140361-17-018662
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-05 18:13:43
Reporting Period:: 2017-05-03

Filing Date:: 2017-05-05
Accepted Time:: 2017-05-05 18:13:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1588972	Recro Pharma Inc.	REPH	()	CA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1440771	Stonepine Capital Management, Llc	919 Nw Bond Street Suite 204 Bend OR 97703		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-05-03	13,808	$7.79	2,860,509	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-03	2,340	$7.79	2,858,169	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-04	172,000	$7.69	2,686,169	No	4	S	Indirect	See Notes
Common Stock	Disposition	2017-05-04	29,160	$7.69	2,657,009	No	4	S	Indirect	See Notes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes
No	4	S	Indirect	See Notes

Footnotes

This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.7768 to $7.977. The Filers undertake to provide to the Issuer, any security holder of the issuer or the SEC staff, on request, information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 6 of this Form 4.
The filers (the "Filers") are Stonepine Capital Management, LLC (the "General Partner"), Stonepine Capital, L.P. (the "Partnership"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of investment funds, including the Partnership (collectively, the "Funds"). Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Funds for the benefit of their investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The General Partner is filing this Form 4 for itself and the other Filers.
The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein.
These securities were sold by the Partnership, which held 2,443,843 shares after the transaction on May 3 and 2,271,843 shares after the transaction on May 4.
These securities were sold by the other Funds.
This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.69 to $7.838.